We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+8.39%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$11.3B
AUM Growth
+$1.62B
Cap. Flow
+$896M
Cap. Flow %
7.96%
Top 10 Hldgs %
56.76%
Holding
110
New
30
Increased
24
Reduced
18
Closed
25

Top Buys

Rank Stock Value
1
EFX icon
Equifax
EFX
+$171M
2
TWX
Time Warner Inc
TWX
+$146M
3
NXPI icon
NXP Semiconductors
NXPI
+$145M
4
KITE
Kite Pharma, Inc.
KITE
+$136M
5
TRU icon
TransUnion
TRU
+$106M

Top Sells

Rank Stock Value
1
MBLY
Mobileye N.V.
MBLY
+$371M
2
SBAC icon
SBA Communications
SBAC
+$132M
3
TMH
Team Health Holdings Inc
TMH
+$105M
4
ALR
Alere Inc
ALR
+$82.4M
5
META icon
Meta Platforms (Facebook)
META
+$75.8M

Sector Composition

Rank Sector Weight
1 Technology 23.58%
2 Healthcare 20.65%
3 Communication Services 20.02%
4 Industrials 7.53%
5 Financials 3.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QCOM icon
76
Qualcomm
QCOM
$169B
$4.41M 0.04%
85,000
– –
BKD icon
77
Brookdale Senior Living
BKD
$2.82B
$3.5M 0.03%
330,000
– –
VYGR icon
78
Voyager Therapeutics
VYGR
$209M
$3.45M 0.03%
+167,665
New +$1.89M
GCVRZ
79
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$2.46M 0.02%
6,827,805
– –
KALA icon
80
KALA BIO
KALA
$15.9M
$2.28M 0.02%
+40
New +$2.19M
DCPH
81
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.9M 0.02%
+100,000
New +$1.83M
NITE
82
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$774K 0.01%
+40,300
New +$870K
ALNY icon
83
Alnylam Pharmaceuticals
ALNY
$31.6B
– –
-200,000
Closed -$16M
AMRN
84
Amarin Corp
AMRN
$298M
– –
-74,750
Closed -$6.03M
FBRX icon
85
Forte Biosciences
FBRX
$1.63B
– –
-267
Closed -$1.2M
H icon
86
Hyatt Hotels
H
$17B
– –
-265,000
Closed -$14.9M
HUM icon
87
Humana
HUM
$45.5B
– –
-178,500
Closed -$43M
PBYI icon
88
Puma Biotechnology
PBYI
$477M
– –
-213,000
Closed -$18.6M
TGNA
89
DELISTED
TEGNA Inc
TGNA
– –
-670,000
Closed -$9.65M
IMGN
90
DELISTED
Immunogen Inc
IMGN
– –
-505,000
Closed -$3.59M
CLVS
91
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-610,000
Closed -$57.1M
IMMU
92
DELISTED
Immunomedics Inc
IMMU
– –
-4,227,500
Closed -$37.3M
PTLA
93
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-855,000
Closed -$48M
PTLA
94
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-250,000
Closed -$14M
AGN
95
DELISTED
Allergan plc
AGN
– –
-227,500
Closed -$55.3M
HZNP
96
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-745,000
Closed -$8.84M
AKAO
97
DELISTED
Achaogen Inc
AKAO
– –
-948,500
Closed -$20.6M
RXDX
98
DELISTED
Ignyta, Inc.
RXDX
– –
-1,153,500
Closed -$11.9M
CAB
99
DELISTED
Cabela's Inc
CAB
– –
-605,000
Closed -$35.9M
WBMD
100
DELISTED
WebMD Health Corp.
WBMD
– –
-679,130
Closed -$39.8M
1 2 3
4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2017 Portfolio in Review

As of Q3 2017, Thomas Steyer held 110 positions worth $11.3B, up 17% from $9.63B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Thomas Steyer deployed $896M of net new capital in Q3 2017, opening 30 new positions and adding to 24 existing holdings. Its largest new stake was Equifax: 1,290,000 shares worth $137M.

By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was SBA Communications, an estimated $132M trimmed.

  • Thomas Steyer's largest Q3 2017 buy was Equifax: 1,290,000 shares worth $137M.
  • Thomas Steyer added most to Time Warner Inc in Q3 2017, an estimated $146M increase.
  • Thomas Steyer's biggest Q3 2017 reduction was SBA Communications, cutting an estimated $132M.
  • Thomas Steyer fully exited Mobileye N.V. in Q3 2017, selling an estimated $371M.
  • Thomas Steyer's ten largest holdings make up 57% of its $11.3B portfolio in Q3 2017.
  • Thomas Steyer opened 30 new positions and closed 25 in Q3 2017.
  • Thomas Steyer's portfolio value rose 17% quarter-over-quarter to $11.3B.

Based on Farallon Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.